Smart Insulin Pen/Smart Cap Bridge Technology Gap for MDI
People living with T1D who prefer multiple daily injections (MDI) of insulin now have two high-tech management options: An insulin smart pen or an insulin smart pen cap.
Vertex Shares Data from Their Stem Cell-Derived Therapy—and It’s Outstanding
In February, Vertex announced they were beginning a clinical trial for VX-880, their stem cell-derived therapy for use in people with type 1 diabetes (T1D). Today, they announced that the first person to receive this therapy now needs 91% less insulin 90 days after receiving an infusion of these fully differentiated cells at just half […]
Breakthrough T1D Mourns the Loss of Stacey Anderson, M.D.
Breakthrough T1D is deeply saddened at the passing of Stacey Anderson, M.D. Dr. Anderson was a tireless champion for the type 1 diabetes (T1D) community, a brilliant researcher, dedicated physician, and longtime Breakthrough T1D partner, grantee, reviewer, and friend. “Dr. Stacey Anderson was a tremendous diabetes champion and she will be terribly missed,” said Breakthrough […]
EASD Conference Will Bring Together—Virtually—Top Minds in Diabetes Research
Leading researchers from around the world will gather for the annual meeting of the European Association for the Study of Diabetes (EASD).
FDA Approves 7-day Infusion Set
Medtronic’s Extended Wear Infusion Set (EWIS) is the first infusion set approved for 7 days, a significantly longer duration; Currently, no other infusion set is approved for more than 3 days.
Vertex Pharmaceuticals Investigating Cell Therapy for Type 1 Diabetes
Vertex is currently enrolling for a clinical trial evaluating their stem cell derived islet cell infusion therapy, VX-880.
Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering
Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to thrive.
Abbott FreeStyle Libre 2 iOS App Receives FDA Approval
On August 2, 2021, Abbott announced the FreeStyle Libre 2 iOS app received approval from the FDA for adults and children ages 4 and up with diabetes.
FDA Approves Semglee® as the First Interchangeable Biosimilar Insulin Product
The U.S. Food and Drug Administration (FDA) approved Semglee® (insulin glargine-yfgn) as the first ever interchangeable biosimilar insulin product. Semglee® (insulin glargine-yfgn) is indicated to improve glycemic control in adults and pediatric people with type 1 and adults with type 2 diabetes, and is biosimilar and interchangeable to Lantus®, a long-acting insulin. In other words, […]
Two Studies Shed Light on Diabetic Kidney Disease
Two recent publications shed light on which people with type 1 diabetes will develop end-stage kidney disease, a complication of diabetes.
